1,458 reports of this reaction
3.2% of all CARISOPRODOL reports
#2 most reported adverse reaction
COMPLETED SUICIDE is the #2 most commonly reported adverse reaction for CARISOPRODOL, manufactured by Viatris Specialty LLC. There are 1,458 FDA adverse event reports linking CARISOPRODOL to COMPLETED SUICIDE. This represents approximately 3.2% of all 45,997 adverse event reports for this drug.
Patients taking CARISOPRODOL who experience completed suicide should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COMPLETED SUICIDE is moderately reported among CARISOPRODOL users, representing a notable but not dominant share of adverse events.
In addition to completed suicide, the following adverse reactions have been reported for CARISOPRODOL:
The following drugs have also been linked to completed suicide in FDA adverse event reports:
COMPLETED SUICIDE has been reported as an adverse event in 1,458 FDA reports for CARISOPRODOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
COMPLETED SUICIDE accounts for approximately 3.2% of all adverse event reports for CARISOPRODOL, making it one of the most commonly reported side effect.
If you experience completed suicide while taking CARISOPRODOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.